Sebastiaan M Bossers1, Stephan A Loer1, Frank W Bloemers2, Dennis Den Hartog3, Esther M M Van Lieshout3, Nico Hoogerwerf4,5, Joukje van der Naalt6, Anthony R Absalom7, Saskia M Peerdeman8, Lothar A Schwarte1,9, Christa Boer1, Patrick Schober1,9. 1. Department of Anesthesiology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. 2. Department of Surgery, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. 3. Trauma Research Unit Department of Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands. 4. Department of Anesthesiology, Radboud University Medical Center, Nijmegen, the Netherlands. 5. Helicopter Emergency Medical Service Lifeliner 3, Nijmegen, the Netherlands. 6. Department of Neurology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. 7. Department of Anesthesiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. 8. Department of Neurosurgery, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. 9. Helicopter Emergency Medical Service Lifeliner 1, Amsterdam, the Netherlands.
Abstract
Importance: The development and expansion of intracranial hematoma are associated with adverse outcomes. Use of tranexamic acid might limit intracranial hematoma formation, but its association with outcomes of severe traumatic brain injury (TBI) is unclear. Objective: To assess whether prehospital administration of tranexamic acid is associated with mortality and functional outcomes in a group of patients with severe TBI. Design, Setting, and Participants: This multicenter cohort study is an analysis of prospectively collected observational data from the Brain Injury: Prehospital Registry of Outcome, Treatments and Epidemiology of Cerebral Trauma (BRAIN-PROTECT) study in the Netherlands. Patients treated for suspected severe TBI by the Dutch Helicopter Emergency Medical Services between February 2012 and December 2017 were included. Patients were followed up for 1 year after inclusion. Data were analyzed from January 10, 2020, to September 10, 2020. Exposures: Administration of tranexamic acid during prehospital treatment. Main Outcomes and Measures: The primary outcome was 30-day mortality. Secondary outcomes included mortality at 1 year, functional neurological recovery at discharge (measured by Glasgow Outcome Scale), and length of hospital stay. Data were also collected on demographic factors, preinjury medical condition, injury characteristics, operational characteristics, and prehospital vital parameters. Results: A total of 1827 patients were analyzed, of whom 1283 (70%) were male individuals and the median (interquartile range) age was 45 (23-65) years. In the unadjusted analysis, higher 30-day mortality was observed in patients who received prehospital tranexamic acid (odds ratio [OR], 1.34; 95% CI, 1.16-1.55; P < .001), compared with patients who did not receive prehospital tranexamic acid. After adjustment for confounders, no association between prehospital administration of tranexamic acid and mortality was found across the entire cohort of patients. However, a substantial increase in the odds of 30-day mortality persisted in patients with severe isolated TBI who received prehospital tranexamic acid (OR, 4.49; 95% CI, 1.57-12.87; P = .005) and after multiple imputations (OR, 2.05; 95% CI, 1.22-3.45; P = .007). Conclusions and Relevance: This study found that prehospital tranexamic acid administration was associated with increased mortality in patients with isolated severe TBI, suggesting the judicious use of the drug when no evidence for extracranial hemorrhage is present.
Importance: The development and expansion of intracranial hematoma are associated with adverse outcomes. Use of tranexamic acid might limit intracranial hematoma formation, but its association with outcomes of severe traumatic brain injury (TBI) is unclear. Objective: To assess whether prehospital administration of tranexamic acid is associated with mortality and functional outcomes in a group of patients with severe TBI. Design, Setting, and Participants: This multicenter cohort study is an analysis of prospectively collected observational data from the Brain Injury: Prehospital Registry of Outcome, Treatments and Epidemiology of Cerebral Trauma (BRAIN-PROTECT) study in the Netherlands. Patients treated for suspected severe TBI by the Dutch Helicopter Emergency Medical Services between February 2012 and December 2017 were included. Patients were followed up for 1 year after inclusion. Data were analyzed from January 10, 2020, to September 10, 2020. Exposures: Administration of tranexamic acid during prehospital treatment. Main Outcomes and Measures: The primary outcome was 30-day mortality. Secondary outcomes included mortality at 1 year, functional neurological recovery at discharge (measured by Glasgow Outcome Scale), and length of hospital stay. Data were also collected on demographic factors, preinjury medical condition, injury characteristics, operational characteristics, and prehospital vital parameters. Results: A total of 1827 patients were analyzed, of whom 1283 (70%) were male individuals and the median (interquartile range) age was 45 (23-65) years. In the unadjusted analysis, higher 30-day mortality was observed in patients who received prehospital tranexamic acid (odds ratio [OR], 1.34; 95% CI, 1.16-1.55; P < .001), compared with patients who did not receive prehospital tranexamic acid. After adjustment for confounders, no association between prehospital administration of tranexamic acid and mortality was found across the entire cohort of patients. However, a substantial increase in the odds of 30-day mortality persisted in patients with severe isolated TBI who received prehospital tranexamic acid (OR, 4.49; 95% CI, 1.57-12.87; P = .005) and after multiple imputations (OR, 2.05; 95% CI, 1.22-3.45; P = .007). Conclusions and Relevance: This study found that prehospital tranexamic acid administration was associated with increased mortality in patients with isolated severe TBI, suggesting the judicious use of the drug when no evidence for extracranial hemorrhage is present.
Authors: Michael C Dewan; Abbas Rattani; Saksham Gupta; Ronnie E Baticulon; Ya-Ching Hung; Maria Punchak; Amit Agrawal; Amos O Adeleye; Mark G Shrime; Andrés M Rubiano; Jeffrey V Rosenfeld; Kee B Park Journal: J Neurosurg Date: 2018-04-01 Impact factor: 5.115
Authors: Haleema Shakur; Ian Roberts; Raúl Bautista; José Caballero; Tim Coats; Yashbir Dewan; Hesham El-Sayed; Tamar Gogichaishvili; Sanjay Gupta; Jorge Herrera; Beverley Hunt; Pius Iribhogbe; Mario Izurieta; Hussein Khamis; Edward Komolafe; María-Acelia Marrero; Jorge Mejía-Mantilla; Jaime Miranda; Carlos Morales; Oluwole Olaomi; Fatos Olldashi; Pablo Perel; Richard Peto; P V Ramana; R R Ravi; Surakrant Yutthakasemsunt Journal: Lancet Date: 2010-06-14 Impact factor: 79.321
Authors: Markus B Skrifvars; Michael Bailey; Jeffrey Presneill; Craig French; Alistair Nichol; Lorraine Little; Jacques Duranteau; Olivier Huet; Samir Haddad; Yaseen Arabi; Colin McArthur; D James Cooper; Rinaldo Bellomo Journal: Intensive Care Med Date: 2016-12-27 Impact factor: 17.440
Authors: G Franschman; N Verburg; V Brens-Heldens; T M J C Andriessen; J Van der Naalt; S M Peerdeman; J P Valk; N Hoogerwerf; S Greuters; P Schober; P E Vos; H M T Christiaans; C Boer Journal: Injury Date: 2012-06-12 Impact factor: 2.586
Authors: Sebastiaan M Bossers; Christa Boer; Frank W Bloemers; Esther M M Van Lieshout; Dennis Den Hartog; Nico Hoogerwerf; Gerard Innemee; Joukje van der Naalt; Anthony R Absalom; Saskia M Peerdeman; Matthijs de Visser; Marcel A de Leeuw; Lothar A Schwarte; Stephan A Loer; Patrick Schober Journal: Prehosp Emerg Care Date: 2020-11-03 Impact factor: 3.077
Authors: Seif Tarek El-Swaify; Mazen A Refaat; Sara H Ali; Abdelrahman E Mostafa Abdelrazek; Pavly Wagih Beshay; Menna Kamel; Bassem Bahaa; Abdelrahman Amir; Ahmed Kamel Basha Journal: Trauma Surg Acute Care Open Date: 2022-01-05
Authors: Ruchira M Jha; Benjamin E Zusman; Ava M Puccio; David O Okonkwo; Matthew Pease; Shashvat M Desai; Matthew Leach; Yvette P Conley; Patrick M Kochanek Journal: JAMA Netw Open Date: 2021-07-01